G1 Therapeutics (GTHX) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GTHX shares.
View GTHX analyst ratings or view top-rated stocks.

6 analysts have issued 12 month price objectives for G1 Therapeutics' shares. Their GTHX share price forecasts range from $10.00 to $25.00. On average, they expect the company's share price to reach $16.60 in the next year. This suggests a possible upside of 533.6% from the stock's current price.
View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts.

G1 Therapeutics' stock was trading at $5.43 at the beginning of 2023. Since then, GTHX stock has decreased by 51.7% and is now trading at $2.62.
View the best growth stocks for 2023 here.

G1 Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,120,000 shares, a drop of 5.7% from the April 30th total of 3,310,000 shares. Based on an average daily volume of 938,200 shares, the short-interest ratio is presently 3.3 days.
View G1 Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our GTHX earnings forecast.

G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.11. The business earned $12.95 million during the quarter, compared to analysts' expectations of $10.54 million. G1 Therapeutics had a negative net margin of 219.66% and a negative trailing twelve-month return on equity of 222.92%.

ETFs with the largest weight of G1 Therapeutics (NASDAQ:GTHX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

G1 Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (5.27%), JPMorgan Chase & Co. (4.16%), BlackRock Inc. (2.68%), FMR LLC (1.87%), Raymond James & Associates (1.45%) and Bank of America Corp DE (1.17%). Insiders that own company stock include Andrew Perry, Glenn P Muir, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends.

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GTHX stock can currently be purchased for approximately $2.62.

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $135.35 million and generates $57.35 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.

The company employs 148 workers across the globe.

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.